CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
Conditions
Brief summary
This phase II trial studies the side effects and best dose of bortezomib when given with chemotherapy and to see how well they work in treating participants with lymphoid malignancies undergoing stem cell transplant. Giving chemotherapy before a stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells called graft versus host disease. Giving tacrolimus and methotrexate after the transplant may stop this from happening. Giving bortezomib and chemotherapy may work better in treating participants with lymphoid malignancies undergoing a stem cell transplant.
Detailed description
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of Velcade (bortezomib) in patients with lymphoid malignancies undergoing allogeneic peripheral blood stem cell or bone marrow transplantation. II. To determine the 1-year disease-free-survival (DFS) and the toxicity profile of Velcade (bortezomib) in patients with lymphoid malignancies undergoing allogeneic peripheral blood stem cell or bone marrow transplantation. SECONDARY OBJECTIVES: I. To compare the incidence of graft versus host disease (GVHD) with historical controls. OUTLINE: This is a dose-escalation study of bortezomib. Participants receive carmustine intravenously (IV) over 1 hour on day -6, cytarabine IV over 1 hour twice daily (BID) on days -5 to -2, etoposide IV over 3 hours BID on days -5 to -2, and melphalan IV over 30 minutes on day -1. Participants also receive rituximab IV on days -13, -6, +1, and +8, and bortezomib IV over 1 minute on days -13, -6, -1, and +2. Participants receiving a matched unrelated or mismatched donor transplant also receive anti-thymocyte globulin IV over 4-6 hours on days -6 and -5. Participants then undergo allogeneic hematopoietic stem cell transplantation over 30-45 minutes on day 0 and receive filgrastim subcutaneously (SC) once daily (QD) starting on day +7 until blood counts return to normal level. Participants receive tacrolimus IV starting on day -2 changing to orally (PO) before leaving the hospital for 6-8 months after the transplant. Participants also receive methotrexate IV over a few minutes on days +1, +3, and +6 and those receiving a matched unrelated or mismatched donor transplant also receive methotrexate IV on day +11. After completion of study treatment, participants are followed up at 1 month, every 3 months for 1 year, and then every 6 months for 5 years.
Interventions
PROCEDUREAllogeneic Hematopoietic Stem Cell Transplantation
Undergo allogeneic hematopoietic stem cell transplantation
BIOLOGICALAnti-Thymocyte Globulin
Given IV
DRUGBortezomib
Given IV
DRUGCarmustine
Given IV
DRUGCytarabine
Given IV
DRUGEtoposide
Given IV
BIOLOGICALFilgrastim
Given SC
DRUGMelphalan
Given IV
DRUGMethotrexate
Given IV
BIOLOGICALRituximab
Given IV
DRUGTacrolimus
Given IV and PO
Sponsors
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 70 Years
Healthy volunteers
No
Inclusion criteria
* Any histological subtype of CD20+ lymphoid malignancies or T-cell lymphoid malignancies. * Patients with CD20+ lymphoid malignancies in relapse after failing \>= 1 prior regimen of conventional treatment and not eligible for non-myeloablative transplant. Patients with T-cell lymphoid malignancies can either be in relapse or newly diagnosed with high risk features (such as high International Prognostic Index \[IPI\] of \>= 2). * Patients with prior non-myeloablative transplant are eligible if not from the same donor. * A fully-matched or one-antigen mismatched sibling or unrelated donor. * Left ventricular ejection fraction (EF) \>= 40% with no uncontrolled arrhythmias or symptomatic heart disease. * Forced expiratory volume in one second (FEV1), forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) \>= 40%. * Serum creatinine \< 1.8 mg/dL. * Serum bilirubin \< 3 X upper limit of normal. * Serum glutamate pyruvate transaminase (SGPT) \< 3 X upper limit of normal. * Voluntary signed, written Institutional Review Board (IRB)-approved informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care. * Men and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.
Exclusion criteria
* Past history of anaphylaxis following exposure to rituximab or Velcade, boron or mannitol. * History of grade 3 or 4 National Cancer Institute (NCI) toxicity with prior Velcade therapy. * Patient with active central nervous system (CNS) disease. * Pregnant (positive beta human chorionic gonadotropin \[HCG\] test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization) or currently breast feeding. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Known infection with human immunodeficiency virus (HIV), human T-lymphotropic virus (HTLV-I), hepatitis B, or hepatitis C. * Patients with other malignancies diagnosed within 2 years prior to study day -13 (except skin squamous or basal cell carcinoma). * Active uncontrolled bacterial, viral or fungal infections. * Major surgical procedure or significant traumatic injury within 4 weeks prior to day -13. * Serious, non-healing wound, ulcer, or bone fracture. * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 3 months prior to day -13. * History of stroke within 6 months. * Myocardial infarction within the past 6 months prior to study day 1, or has New York Heart Association (NYHA) class III or IV heart failure or arrhythmia, unstable angina, uncontrolled congestive heart failure or arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiography (ECG) abnormality at screening must be documented by investigator as not medically relevant. * Uncontrolled hypertension (\>= 140/90). * Uncontrolled chronic diarrhea. * A prior allogeneic transplant from the same donor. * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Patient has received other investigational drugs within 3 weeks before enrollment. * Active peripheral neuropathy greater or equal to grade 2.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicity (DLT) | From start of treatment to 90 days after the start of treatment | To determine the maximum tolerated dose(MTD) of velcade and dose limiting toxicity(DLT). A dose limiting toxicity (DLT) was defined as a grade 3-4 neurological toxicity, graft failure, or death due to GvHD. The Commom Terminlogy Criteria for Adverse Events v3.0 was used. |
| Disease-free Survival | At 1 year | To determine DFS at 1 year post transplant. |
Countries
United States
Participant flow
Recruitment details
Patients enrolled at MD Anderson clinic from February 2007 through May 2011.
Participants by arm
| Arm | Count |
|---|---|
| Velcade Dose Level 1 BEAM + Rituxan + ATG(MUD pts only) + Velcade (1-1.3mg/m2) + ALLO SCT | 36 |
| Velcade Dose Level 2 BEAM + Rituxan + ATG(MUD pts only) + Velcade 1.3mg/m2 + ALLO SCT | 3 |
| Velcade Dose Level 3 BEAM + Rituxan + ATG(MUD pts only) + Velcade 1.6mg/m2 + ALLO SCT | 0 |
| Total | 39 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Patient was taken off study for non-comp | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Velcade Dose Level 1 | Velcade Dose Level 2 | Velcade Dose Level 3 | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 36 Participants | 3 Participants | 0 Participants | 39 Participants |
| Age, Continuous | 54 years | 58 years | — | 54 years |
| Breakdown of Disease by Number of Participants in each Dose Level CLL | 12 Participants | 1 Participants | — | 13 Participants |
| Breakdown of Disease by Number of Participants in each Dose Level Folicular Lymphoma | 8 Participants | 0 Participants | — | 8 Participants |
| Breakdown of Disease by Number of Participants in each Dose Level Large Cell Lymphoma | 9 Participants | 2 Participants | — | 11 Participants |
| Breakdown of Disease by Number of Participants in each Dose Level Mantle Cell Lymphoma | 2 Participants | 0 Participants | — | 2 Participants |
| Breakdown of Disease by Number of Participants in each Dose Level Marginal Zone Lymphoma | 1 Participants | 0 Participants | — | 1 Participants |
| Breakdown of Disease by Number of Participants in each Dose Level T-Cell Lymphoma | 4 Participants | 0 Participants | — | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 5 Participants | 0 Participants | — | 5 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 4 Participants | 0 Participants | — | 4 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 27 Participants | 3 Participants | — | 30 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants | 0 Participants | — | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants | 0 Participants | — | 2 Participants |
| Race (NIH/OMB) White | 32 Participants | 3 Participants | — | 35 Participants |
| Region of Enrollment United States | 36 participants | 3 participants | — | 39 participants |
| Sex: Female, Male Female | 8 Participants | 1 Participants | — | 9 Participants |
| Sex: Female, Male Male | 28 Participants | 2 Participants | — | 30 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 6 / 36 | 2 / 3 | 0 / 0 |
| other Total, other adverse events | 36 / 36 | 3 / 3 | 0 / 0 |
| serious Total, serious adverse events | 6 / 36 | 2 / 3 | 0 / 0 |
Outcome results
Primary
Disease-free Survival
To determine DFS at 1 year post transplant.
Time frame: At 1 year
Population: Patients up to 70 years of age with any histological subtype of CD20+ lymphoid malignancy or T-Cell lymphoid malignancy who were not eligible for a non-myeloablative transplant.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemotherapy, Transplant, Filgrastim, Tacrolimus) | Disease-free Survival | 16 Participants |
| Velcade Dose Level 2 | Disease-free Survival | 0 Participants |
| Velcade Dose Level 3 | Disease-free Survival | 0 Participants |
Primary
Number of Participants With Dose Limiting Toxicity (DLT)
To determine the maximum tolerated dose(MTD) of velcade and dose limiting toxicity(DLT). A dose limiting toxicity (DLT) was defined as a grade 3-4 neurological toxicity, graft failure, or death due to GvHD. The Commom Terminlogy Criteria for Adverse Events v3.0 was used.
Time frame: From start of treatment to 90 days after the start of treatment
Population: Patients up to 70 years of age with any histological subtype of CD20+ lymphoid malignancy or T-Cell lymphoid malignancy who were not eligible for a non-myeloablative transplant.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Treatment (Chemotherapy, Transplant, Filgrastim, Tacrolimus) | Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Velcade Dose Level 2 | Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |
| Velcade Dose Level 3 | Number of Participants With Dose Limiting Toxicity (DLT) | 0 Participants |